Health Technology Assessment

The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local Needs to Global Opportunities. Several members of the OHE team will attend and participate in the conference.

Just published is a new book entitled “Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions”. It features a chapter by OHE’s Martina Garau and Professor Nancy Devlin on opportunities and challenges of MCDA in HTA.

OHE’s Koonal Shah gave a presentation on the evidence of societal support for an end of life premium at the Pharmaccess Leaders Forum in Milan on 5th May.

The fourth annual meeting of the HTAi Asia Policy Forum was held in November 2016. OHE produced Background Briefing Papers for each of these four meetings covering a variety of topics relevant to the development of HTA in Asia, all of which are now available. This post contains a summary of each report.

A new OHE Research Paper entitled “Age and Utilities: Issues for HTA” is available to download.

OHE’s Yan Feng, Mike Herdman, David Parkin and Nancy Devlin have a new paper in Quality of Life Research to exploring whether patients’ self-reported pain can be compared and aggregated in multi-country studies

There are three EQ-5D value sets available for use in cost effectiveness analysis in the UK and/or England:

- the UK EQ-5D-3L value set (often called the ‘MVH’ value set) which has been used for two decades, e.g. in evidence submitted to NICE (Dolan, 1997);
- a ‘crosswalk’ value set (van Hout et al., 2012), which maps patients’ EQ-5D-5L data to the EQ-5D-3L descriptive system, so that the MVH value set can be applied; and
- the EQ-5D-5L value set for England (Devlin et al., 2016).

How do these value sets differ? And how important are these differences likely to be for users?

A new OHE Research Paper by Mulhern et al. (2017) compares the characteristics of the value sets.

OHE’s Professor Nancy Devlin and co-author Richard Brooks have published a new paper that provides an overview of the development of the EQ-5D; the current state of play; and what the future might hold for the further development and use of EQ-5D instruments in HTA and other applications.

A new OHE report compares the availability and access of orphan medicinal products (OMPs) in the UK, France, Germany, Italy and Spain.

Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the 2016 ICER Membership Policy Summit.

Pages

Subscribe to RSS - Health Technology Assessment